AI for prostate cancer diagnosis - hype or today's reality?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. The Use of Artificial Intelligence in Urologic Oncology: Current Insights and Challenges.Research and reports in urology · 2025
   Review
2. Harnessing artificial intelligence for prostate cancer management.Cell reports. Medicine · 2024
   Review
3. Bioinformatics in urology - molecular characterization of pathophysiology and response to treatment.Nature reviews. Urology · 2024
   Review
4. Deep Learning Approaches in Histopathology.Cancers · 2022
   Review
5. Outsmarting Metastatic Prostate Cancer: Integration of Imaging, Liquid Biopsies and Biomarkers With Artificial Intelligence.Technology in cancer research & treatment
   Review

Corrections and comments

• Comment on
  Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.2022

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as